fda compounded semaglutide ban Novo Nordisk asks to Ozempic, Wegovy copies US FDA flags dosing risks
Description
Sitagliptin, the first approved DPP-4 inhibitor, was developed by a group led by Nancy Thornberry and Ann Weber at Merck and lowered HbA1c by ~0.8% as a monotherapy with a highly significant reduction of ~1.9% when icombined with metformin (1)

Jastreboff AM, Kaplan LM, Frias JP, et al

Whether you're on Ozempic, Wegovy, or another GLP-1 medication, every dish is crafted to align with expert nutrition guidance: Territory makes it easy to stay consistent with meals that do the work for you

7.5 mg/0.5mL

Even simple movements, like walking uphill, sitting upright at a desk, or lifting a bag, now demand more from tissues that arent conditioned for it
